Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Firsekibart vs betamethasone for acute gouty arthritis in CKD stage 3–5 (real-world cohort)
ChiCTR2600122077Phase 4Not yet recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Apr 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of genakumab in gout and chronic kidney disease (CKD) (2 arms), sponsored by Zhongshan Hospital, Fudan University. Primary endpoint: Proportion of patients with at least one recurrence of gout within 12 weeks. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
genakumab
03
Conditions
goutchronic kidney disease (CKD)
Beyond the preview
Go deeper on ChiCTR2600122077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600122077.